
Shares of Honasa Consumer Ltd, the parent of Mamaearth, rose as much as 12% on Tuesday, 6 October, after the company projected net sales value growth in the early thirties year-on-year for the July to September 2026 quarter, driven by broad-based traction across brands and offline channels. The stock hit an intraday high of Rs 493 on the NSE, according to The Hindu Business Line, while Livemint reported Rs 492.90. Business Standard put the surge at 10.5% to Rs 488.10, near its 52-week high of Rs 509.90, and CNBC-TV18 reported a 7.5% gain to Rs 470.6.

Mamaearth, Honasa's largest brand, is expected to deliver high-teens NSV growth, supported by rising brand affinity and a widening offline footprint. Younger brands, including The Derma Co, Aqualogica, and BBlunt, are projected to accelerate to around mid-forties growth. The company guided for an early double-digit operating margin in Q2, with strong year-on-year improvement. Offline channels, including general trade and modern trade, are expected to lead growth.
Honasa cautioned that the update is provisional and subject to limited review by statutory auditors. Detailed financial results will follow board approval. Livemint reported on 7 October that the update may raise FY27 earnings expectations but noted that sustaining operating leverage through wider distribution will be crucial.
Across the 11 outlets, coverage of Honasa's projection is uniform straight reporting of the company's exchange filing, with each outlet leading on the share surge and the NSV guidance. The Hindu Business Line adds the traded value and order-flow data, Business Standard cites Kotak Securities' upgrade to 'Buy' with a target of Rs 580, and Livemint's 7 October piece is the most analytical, questioning whether the early double-digit margin can be sustained once advertising and trade incentives are added back. Inc42 and entrackr also fold in background on Project Neev and the Fluence Pharma deal that are not in the filing. The only factual divergence is the intraday high: Rs 493.00 for Business Line versus Rs 492.90 for Livemint. All sources agree the stock is near its 52-week high, and none disputes the provisional nature of the guidance.
HDFC Securities maintained its 'Buy' rating with a target of Rs 550, citing strong growth at Mamaearth and The Derma Co., expanding offline reach, and the potential of younger brands.
Coverage: 11 sources, 11 neutral
Sources (11): cnbctv18.com (neutral report), ndtvprofit.com (neutral report), economictimes.indiatimes.com (neutral report), livemint.com (neutral report), inc42.com (neutral report), thehindubusinessline.com (neutral report), entrackr.com (neutral report), economictimes.indiatimes.com (2) (neutral report), business-standard.com (neutral report), livemint.com (2) (neutral report), livemint.com (3) (neutral report)
This brief was synthesised by AI from the 11 sources linked above, so one read covers every framing they carry. Methodology and corrections.
Update, 9 October 2026: this story now draws on 11 sources.